Skylar Jeremias

Dr. Parth Rali, MD, of Temple University Hospital explained the challenges of managing patients with intermediate-risk pulmonary embolism (PE) and how risk stratification tools can help to address these challenges.

Health equity coverage appearing in the October 2023 issue of Evidence-Based Oncology.

Phase 3 data presented at ISPAD found that teplizumab-mzwv (Tzield) was better at slowing the progression of type 1 diabetes (T1D) in newly diagnosed children and adolescents.

No differences in mammography completion were observed between an automated opt-out vs an opt-in patient outreach program for breast cancer screening, according to a randomized controlled trial. However, differences in administration burden between programs could lead clinics to prefer one over the other.

A study assessing an experimental cell-free DNA myelination liquid biopsy test was found to be 91% accurate at identifying early-stage epithelial ovarian cancer.

Researchers found that heated tobacco products can reduce risks of exacerbations and exposure to toxic chemicals compared with combustible cigarettes in patients with chronic obstructive pulmonary disease (COPD).

Operational forecasting for patients who are eligible for gene therapies will be crucial for addressing the accessibility and affordability challenges with these agents, especially as more gene therapies are expected to enter the market in the next few years.

During a session at AMCP Nexus, panelists provided a historical overview on the 340B drug discount program, highlighting the intentions of the plan and the research gaps leading to misconceptions about the program and whether it’s working to lower costs for patients.

Speakers at AMCP Nexus 2023 reviewed the major changes resulting from the Inflation Reduction Act (IRA) that impacted Medicare in 2023 and previewed the new provisions being implemented in the coming years.

At AMCP Nexus, Evernorth's Aimee Tharaldson, PharmD, provided an overview of which medications the FDA has approved in 2023 and what’s to come in nononcology areas over the next 5 years, including new drugs for Alzheimer disease, hemophilia, and nonalcoholic steatohepatitis (NASH).

Panelists at AMCP Nexus provided an overview of the US obesity epidemic, dispelling myths about the causes of obesity, highlighting racial and economic disparities across the nation, and tackling how the managed care space can ensure accessibility to care for all patients.

A session at AMCP Nexus on the use of artificial intelligence (AI) and machine learning (ML) in managed care highlights some real-world examples of successful implementation of these technologies.

The level of biosimilar market sustainability differs between countries, largely due to variances in biosimilar policies and years of experience managing a biosimilar market.

The annual fall meeting of AMCP Nexus 2023 will feature discussions on the evolving managed care landscape, including the impact of the Inflation Reduction Act, the specialty pharmaceutical pipeline, insight into the growing use of diabetes drugs for weight loss, and more.

The FDA has approved Tofidence, the first tocilizumab biosimilar in the United States, which will be used to treat rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

A new study confirmed the validity of a blood test that can diagnose patients with GLUT1 deficiency syndrome, a treatable neurometabolic disease that causes a wide range of neurologic symptoms in children and adults, including seizures.

A report from the Association for Accessible Medicines (AAM) highlighted the value of biosimilars and generics, revealing that lower-cost versions of originator products accumulated $408 billion for the US health care system in 2022.

Cordavis is a new subsidiary from CVS Health Corporation that will work with manufacturers to commercialize and coproduce biosimilars, beginning with an adalimumab product.

The FDA approved a higher dosage of aflibercept (Eylea) for the treatment of age-related macular degeneration, macular edema, and diabetic retinopathy.

The Biden administration has released the first 10 drugs subject to price negotiation with Medicare under the Inflation Reduction Act (IRA), and among those chosen were Stelara (ustekinumab) and Enbrel (etanercept), both of which will face biosimilar competition within the next decade.

Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, highlights several potential strategies to address the historic lack of diversity in multiple myeloma clinical trial populations.

Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at Dana-Farber Cancer Institute, discussed the uptake of zanubrutinib for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL).

Researchers and organizations must collaborate to address the persistent disparities in access to treatments for multiple myeloma, explained Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation.

Interviews on research presented at the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany

Full team coverage from the European Hematology Association 2023 Hybrid Congress, which took place June 8-11 in Frankfurt, Germany.

Coverage of research presented by Strategic Alliance Partners: OneOncology, Florida Cancer Specialists & Research Institute, and The US Oncology Network.

A white paper crafted by the Association for Accessible Medicines (AAM) outlined that main causes of generic drug shortages and recommended several actions for stakeholders to remedy current shortages and prevent future ones.

Data from the Survey of Unmet Needs in Chronic Myeloid Leukemia (CML SUN) trial show that quality of life (QOL) and shared decision-making are priorities for patients, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.

Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed the manufacturing challenges sometimes seen with chimeric antigen receptor (CAR) T-cell therapies and strategies being implemented to improve access for historically underserved patients.

Franco Locatelli, MD, PhD, head of the Department of Pediatric Hematology and Oncology at IRCCS Bambino Gesu Children’s Hospital in Rome, discusses the treatment of both adult and pediatric patients with chronic graft versus host disease (cGvHD).